Phaseline

Targets › PDE9A

PDE9A (High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology.

Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP. Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. (UniProt, O76083)

Open in Phaseline: the race on PDE9A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImaraTovinontrine (IMR-687)
Phosphodiesterase 9A inhibitor
PDE9APhase 2Sickle Cell Disease–

Conditions

Sickle Cell Disease (1)

Modalities

small molecule (1)

Companies

Imara (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.